Replies to post #228521 on Biotech Values

[DewDiligence]

Nestlé acquires AIMT @$34.50 in cash—a 174% premium to Friday’s closing price:

https://www.businesswire.com/news/home/20200830005025/en

The nominal deal value is $2.6B. The 174% premium is one of the largest ever for a biotech deal of this size.

Nestle already owned ~20% of AIMT based on investments dating back to 2016 and including, most recently, a $200M addition following FDA approval of Palforzia (#msg-153675586).